Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib
Eric J. Niesor, Guy Boivin, Éric Rhéaume, Rong Shi, Véronique Lavoie, Nathalie Goyette, Marie-Ève Picard, Anne Perez, Fouzia Laghrissi‐Thode, Jean‐Claude Tardif
Abstract
of 14.4 μM, suggesting stable protease-drug interaction. The inhibitory effect of dalcetrapib on the SARS-CoV-2 3CL protease and viral replication warrants its clinical evaluation for the treatment of COVID-19.
Topics & Concepts
ProteaseCysteine proteaseChemistryCysteineViral replicationIC50BiochemistryEnzymeVirologyIn vitroBiologyVirusSARS-CoV-2 and COVID-19 ResearchComputational Drug Discovery MethodsCell death mechanisms and regulation